Vaccinex (NASDAQ:VCNX) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Vaccinex (NASDAQ:VCNX) from a sell rating to a hold rating in a research note released on Friday morning, Zacks.com reports.

According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

VCNX opened at $4.09 on Friday. The company has a 50 day simple moving average of $5.33. The firm has a market cap of $46.98 million and a PE ratio of -0.79. Vaccinex has a 12 month low of $3.32 and a 12 month high of $12.00.

Vaccinex (NASDAQ:VCNX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.04). The firm had revenue of $0.09 million during the quarter. Research analysts predict that Vaccinex will post -2.35 earnings per share for the current fiscal year.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.

Read More: What is a blue-chip stock?

Get a free copy of the Zacks research report on Vaccinex (VCNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.